Skip to content

Intravascular Ultrasound guidaNce versuS angIoGrapHy Guidance in Patients With ST-segment Elevation Myocardial Infarction

Intravascular Ultrasound guidaNce versuS angIoGrapHy Guidance in Primary percuTaneous Coronary Intervention for Patients With ST-segment Elevation Myocardial Infarction

Status
Not yet recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07616024
Acronym
INSIGHT-STEMI
Enrollment
2488
Registered
2026-05-29
Start date
2026-06-01
Completion date
2032-12-31
Last updated
2026-06-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

PCI, STEMI

Keywords

STEMI, PCI, IVUS

Brief summary

STEMI represents the subtype of ACS with the worst prognosis, associated with high mortality and an elevated risk of complications. The use of IVI guidance holds the potential to reduce the incidence of MACE. In previous studies, there has been limited research on intravascular imaging in the context of primary revascularization procedures for STEMI, and no large-scale cohort study has compared the differences in clinical outcomes between IVI-guided and angiography-guided primary revascularization. Therefore, we conducted this large-scale randomized controlled trial to compare IVI-guided primary PCI versus coronary angiography-guided primary PCI in patients with STEMI.

Detailed description

This study is a prospective, multicenter, randomized controlled, superiority clinical trial. Eligible subjects who meet the inclusion/exclusion criteria will be randomly assigned in a 1:1 ratio to either the IVUS-guided strategy (experimental group) or the conventional coronary angiography-guided strategy (control group). The study plans to enroll at least 2488 subjects, with 1244 subjects in each of the experimental and control groups. Zhongshan Hospital, Fudan University serves as the lead center. A competitive enrollment approach will be adopted, with the number of cases enrolled by the lead center not exceeding 50% of the total sample size. In the IVUS group, intravascular ultrasound (IVUS) will be used for guidance; the use of high-frequency intravascular ultrasound (resolution ≥ 50 MHz) is encouraged, though not mandatory.

Interventions

a catheter equipped with an ultrasound transducer is advanced over a guidewire into the vessel lumen distal to the target coronary lesion. Then, while slowly withdrawing the catheter, 360-degree cross-sectional images of the vessel are acquired to accurately measure lumen dimensions, assess plaque characteristics, select an appropriately sized stent, and confirm that after stent implantation the stent is fully apposed, well expanded, and free of vascular complications.

PROCEDURECoronary angiography guidance

A catheter is inserted through a peripheral artery (e.g., femoral or radial artery) and advanced to the ostium of the coronary arteries under fluoroscopic guidance. Once positioned, contrast medium is injected while X-ray images are acquired to visualize the coronary artery lumen and detect any stenoses or occlusions.

Sponsors

Shanghai Zhongshan Hospital
Lead SponsorOTHER
Shanghai 10th People's Hospital
CollaboratorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
DIAGNOSTIC
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. Patients diagnosed with acute ST-segment elevation myocardial infarction (STEMI) who have an indication for emergency interventional therapy; 2. Subjects who are eligible to undergo primary percutaneous coronary intervention (PCI); 3. Subjects or their authorized family members voluntarily agree to participate in the clinical trial and sign the written informed consent form; 4. The IVUS catheter is expected to pass through the target lesion to complete the examination.

Exclusion criteria

1. Patients with cardiogenic shock or severe heart failure (Killip class IV); 2. Patients who have previously undergone coronary artery bypass grafting (CABG); 3. Patients with coma or disturbance of consciousness; 4. Patients who are expected to be intolerant to long-term antiplatelet therapy; 5. Pregnant women; 6. Life expectancy \< 1 year; 7. Currently participating in another drug/device clinical trial and not having reached the primary endpoint; 8. Poor compliance, expected to be unable to complete follow-up.

Design outcomes

Primary

MeasureTime frameDescription
Primary target vessel failure (TVF) rate1 yeardefined as the composite endpoint of cardiac death, ischemia-driven target vessel revascularization, and target vessel-related myocardial infarction.

Secondary

MeasureTime frameDescription
Lesion success ratePerioperativeLesion success assessed by coronary angiography and lesion success rate assessed by IVUS.
Clinical success ratePre-dischargeLesion success assessed by coronary angiography and lesion success rate assessed by IVUS.
Mortality rate1 YearIncludes cardiovascular death, non-cardiovascular death, and death of undetermined cause
Incidence of myocardial infarction1 yearincludes periprocedural myocardial infarction as defined by SCAI and spontaneous myocardial infarction (infarct-related artery-related vs. non-infarct-related artery-related; culprit lesion-related vs. non-culprit lesion-related)
Revascularization1 yearincludes ischemia-driven and non-ischemia-driven revascularization, revascularization of infarct-related and non-infarct-related arteries, revascularization of culprit and non-culprit lesions, revascularization of target vessels and non-target vessels, and revascularization of target lesions and non-target lesions
Stent thrombosis1 yearAcademic Research Consortium

Countries

China

Contacts

CONTACTChenguang Li, Doctor
li.chenguang@zs-hospital.sh.cn+8613816767665
PRINCIPAL_INVESTIGATORJunbo Ge, Doctor

Fudan University

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jun 19, 2026